Search

Displaying results 3081 - 3090 of 10000 in total
  1. Target

    E3 ubiquitin ligase TRAF3IP2

    go.drugbank.com/bio_entities/BE0011632
    TargetHumans

    Transfers ubiquitin from E2 ubiquitin-conjugating enzyme UBE2V1-UBE2N to substrate protein (PubMed:19825828). … Upon IL17A stimulation, interacts with IL17RA and IL17RC receptor chains through SEFIR domains and catalyzes 'Lys-63'-linked polyubiquitination of TRAF6, leading to TRAF6-mediated activation of NF-kappa-B

    Synonyms: Connection to IKK and SAPK/JNK
  2. Drug

    Potassium guaiacolsulfonate

    go.drugbank.com/drugs/DB13735
    ApprovedWithdrawn

    Guaiacolsulfonate is an aromatic sulfonic acid. Potassium guaiacolsulfonate salt is an expectorant that thins the mucus in the lungs and reduces chest congestion.

    Mixtures: GAYABEN 150 ML SURUP, ARTU 100 ML SURUP
  3. Drug

    CERE-110

    go.drugbank.com/drugs/DB05898
    Investigational

    CERE-110 is a gene-therapy product that involves in vivo delivery of nerve growth factor (NGF) genes through an adeno-associated viral vector (AAV) delivery system. … This drug is developed by Ceregene and currently under phase I of clinical trial.

  4. Indication

    Ovulation Absent

    go.drugbank.com/conditions/DBCOND0140456
    Drugs: Letrozole
    Synonyms: Female infertility due to anovulation (disorder)
  5. Drug

    Tideglusib

    go.drugbank.com/drugs/DB12129
    ApprovedInvestigationalWithdrawn

    It is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3). … [A31601] Tideglusib is being developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment of Alzheimer's disease as of 2012.

  6. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [A189207] Ubrogepant was approved by Health Canada on November 10, 2022. … [A189207,A189213] Previous agents within this class were efficacious but limited by liver toxicity - this led to the development of ubrogepant, which was designed to be a hepatoxicity-free alternative

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Inhibitors
  7. Drug

    MK-2748

    go.drugbank.com/drugs/DB15371
    Investigational

    MK-2748 is under investigation in clinical trial NCT01593735 (A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1)).

  8. Drug

    Human vaccinia virus immune globulin

    go.drugbank.com/drugs/DB14112
    ApprovedInvestigational

    The IgG fraction is purified by the anion-exchange column chromatography method and the solution is solvent/detergent-treated to sterilize the compound [A33814]. … Nevertheless, VIG by virtue of the way it is produced is a poorly characterized and highly variable human product that is only available in very limited quantities - all factors that may intervene with

    Categories: Immunoglobulin G, Human Immunoglobulin G
  9. Drug

    Vusolimogene oderparepvec

    go.drugbank.com/drugs/DB23008
    ApprovedInvestigational

    [L64061] The virus is engineered to express a fusogenic glycoprotein derived from gibbon ape leukemia virus (GALV-GP-R–) and human granulocyte-macrophage colony-stimulating factor (GM-CSF), and has its … promoting dendritic cell and monocyte activation to drive an anti-tumor immune response.

  10. Drug

    Moxetumomab pasudotox

    go.drugbank.com/drugs/DB12688
    ApprovedInvestigational

    This antibody was used to generate a recombinant immunotoxin in which a stabilized Fv segment by a disulfide bond is fused to the _Pseudomonas_ exotoxin A (PE38) which does not have the cell-binding portion … [A38864] MxP appears as an improved form of BL22 by the mutation of the Fv region and the antibody phage-displayed. As well the residues SSY in the heavy chain are mutated to THW.